Breaking Research News from sources other than Breastcancer.org
Comments
-
Lumpie and others, thanks for all these news items. All are so interesting!
0 -
Prognostic and Clinical Significance of Syndecan-1 Expression in Breast Cancer
- This meta-analysis assessed the clinical significance of syndecan-1 (SDC1; also called CD138) expression in 1305 breast cancer patients from nine eligible studies.
- Increased SDC1 protein expression in breast cancer was significantly associated with worse prognosis in terms of disease-free and overall survival, and an aggressive phenotype was associated with negative ER expression and positive HER2 expression.
0 -
Muddling: I am so glad to know that they are helpful to you!
0 -
Lumpie, we don't tell you enough but you are performing a huge service for us all!! xxoo Thank you!!
0 -
Yup, me too! This is in my favorites and I appreciate all the information you all post.
Thank you!
0 -
Let me join the chorus of appreciation for Lumpie and everyone else who contributes to this forum. The information you post is very valuable. A big thank you to all!
0 -
I'll chime in also. Great info. Especially like way you present the items with a review that allow us 'preview' of the info so we can determine if the full report pertains to us personally.
0 -
Keep them coming! It's in my faves too.
0 -
Thanks to everyone for your kind encouragement. It's made my weekend!!
0 -
Yes, thank you so much! I always check this thread when it comes up in Active Topics, and it's basically always you!
"Pharmacy benefit manager (PBM) Delays for Cancer Drugs May Risk Lives, Warn Oncologists"
This one is so infuriating. The synopsis is very well done. ARGH
0 -
Yes Lumpie you have a beautiful , theoretical mind and use it to the benefit of others...what a lovely woman !!
0 -
Add me as an avid member of the Lumpie Appreciation Club!
!Lyn
0 -
I am a fan too. This Board is clear succinct and helpful to us all. Thank you Lumpie, Marijen and others who contribute!
❤️
0 -
Hello ladies, any input regarding TCx4 v TCx6? I already did TC 5/6, I’m thinking of stopping. Per my first Onco TCx4 is the standard but my second Onco recommended TCx6. I’m not finding any study that TCx6 is superior to TCx4.
0 -
Performance Improvement Sustained After DBT Adoption
Early improvement after adoption of digital breast tomosynthesis {3D mammogram} seen regardless of DBT volume
Performance improvements after adoption of digital breast tomosynthesis (DBT) relative to digital mammography (DM) performance have been sustained, regardless of DBT volume, according to a study published online Feb. 26 {2019} in Radiology.
"Patients with or without dense breasts benefit from lower recall rates with 3D mammography and there is no trade off with cancer detection,"
The researchers found that the DM recall rate was 10.4 percent and the cancer detection rate was 4.0 per 1,000 cases before DBT adoption. The DBT recall rate was 9.4 percent and the cancer detection rate was 4.6 per 1,000 cases after DBT adoption.
https://www.practiceupdate.com/C/80404/56?elsca1=e...
0 -
Thanks once again for the kind words and encouragement everyone!
Anxious789: I have not had time to research. I kind of think 6 rounds is standard of care. I assume we are talking about early stage vs. MBC? I took a quick look at NCCN guidelines and (to my surprise) did not see a number of rounds cited. Will check and post if I find anything useful.
0 -
Add me to the LAC, also! Your posts are extremely helpful and really bring tons of research in front of us all, where I for one, may have totally missed it. Many thanks. Mame
0 -
Ditto - I always appreciate Lumpie's posts here - thank you!
0 -
Yes, Lumpie, thank you!
0 -
in 2013 the standard of care for HER2+ TCHP was 6 rounds - one round every three weeks. That's if you qualified for Perjeta - otherwise TCH. Then Herceptin (and maybe Perjeta) every 3 weeks to a total of 17 rounds. I don't think that has changed.
Some docs prefer AC, but since both Adriamicyn & Herceptin effect the heart, the infusion schedule has to change. Possibly Taxol instead of Taxotere with the Herceptin after the AC
0 -
I need to add my voice to the chorus of thanks for all your efforts as well, Lumpie! Your efforts are so very much appreciated!
0 -
thank you very much Lumpie
0 -
Old drugs bring new hope to a cancer that lacks precision therapy {TNBC}
"We think we may have found a way to treat resistant breast cancers that currently have no targeted therapy by repurposing two older drugs, metformin and heme, that are already in the marketplace,"
patients who take metformin for diabetes are less likely to develop cancer. The drug has a direct anti-cancer effect that can repress the proliferation of tumor cells.
heme, marketed as panhematin, ... was first crystallized from blood in 1853. It is now used to treat defects of heme synthesis.
"...We found that this novel combination, hemin plus metformin, can suppress tumor growth, and we validated this in mouse tumor models."
The findings... could extend beyond breast cancer {to}...many cancers, including lung, kidney, uterus, prostate and acute myeloid leukemia.
https://www.uchicagomedicine.org/forefront/cancer-...
0 -
I hv been on metfomin since first diagnosed. I asked my MO about it since I read about the anti-cancer properties and he gave me a scrip. I don't notice it at all - zero SEs.
0 -
Impact of Subtype on Survival of Young Patients With Stage IV Breast Cancer
- In this study of SEER data, 6302 patients with de novo stage IV breast cancer who were <60 years of age were identified and assessed to determine differences in overall survival based on age and disease subtype. Patients <40 years had a significantly higher proportion of HER2+ cancer, a lower proportion of HR+/HER2− disease, and significantly longer median overall survival (45 months vs 33 months) compared with patients aged 40 to 59 years with the exception of those with triple-negative disease.
- Additional studies are warranted to investigate potential underlying mechanisms.
- Compared with those aged 40 to 59 years, patients with de novo metastatic breast cancer aged < 40 years experienced significantly longer survival, except in the setting of triple-negative disease. Distinct treatment-related or biological factors may exist between earlier stage and metastatic breast cancers; further examination of the potential reasons for our findings are warranted.
- https://www.practiceupdate.com/c/80274/67/13/?elsc...
- https://www.clinical-breast-cancer.com/article/S15...(18)30604-9/fulltext
- DOI: https://doi.org/10.1016/j.clbc.2019.01.005
0 -
Lumpie - thanks for continuously posting such great stuff. Saw this one this morning and thought it would be good to also share here:
https://www.dana-farber.org/newsroom/
Basically this says there is evidence that taking a break from Ibrance may reverse resistance, which is pretty exciting
0 -
Hi santabarbarian,
What maintenance dose of Metfomin does your Dr. have you on?
Thanks,
Susan
0 -
I am taking 500 mg twice a day, am and pm. So 1000 total.
0 -
Thank-you,
Susan
0 -
Should Medicare Part B Drugs Get Budget Cap?
MedPAC commissioners discuss ways to lower prices in the program
March 08, 2019
Should there be a cap on Medicare's Part B drug budget? That was one of the options that members of the Medicare Payment Assessment Commission (MedPAC) mentioned here Thursday in a discussion of pricing alternatives.
The binding arbitration model (known as "baseball arbitration") could be used for products with limited competition that exceed a specified cost threshold...
...this model also has the advantage of potentially lowering prices for beneficiaries and taxpayers, although some people may raise concerns about access to drugs if manufacturers decide not to participate in arbitration, which would mean Medicare couldn't cover the drug.
"there is some real danger in treating similar drugs for payment purposes as equivalent for effectiveness and side effects, so I want to be clear there's an ability to provide appropriate treatment,"
The commission did not take any vote on the drug pricing proposals; commission staff will continue working on the issue and it may appear in MedPAC's June report, a spokesman said.
https://www.medpagetoday.com/publichealthpolicy/me...
0
